A spotlight on…Volition’s Commercialisation Strategy

September 05, 2022

Gael Forterre is the Chief Commercial Officer at Volition. Since joining the team in 2021, he has focused on growing our team, overseeing our commercial strategy, launching products, and more.

Find out what Gael and his team have been up to over the past months:

Volition 230621
Volition’s Commercialisation Strategy

Nu.Q® Vet Cancer Test Update

So far this year, Volition has signed an exclusive $28 million License and Supply Agreement with Heska Corporation to distribute the Nu.Q® Vet Cancer Test at the Point of Care.

At the moment, Gael’s commercial team is working closely with Heska, transferring Volition’s technology, and preparing the launch and marketing strategies of the point-of-care version of the product, ready for launch in the US, with Europe to follow.

On top of that, Volition Veterinary continues to work with Texas A&M University, while also launching the Nu.Q® Vet Cancer Test in Asia through its appointed distributor, SAGE Healthcare.

Nu.Q® NETs Launch

After achieving a CE mark for our Nu.Q® NETs product in Europe, we are excited for our Nu.Q® NETs test to be included in a range of studies in the U.S, including a clinical study taking place at the University of Texas MD Anderson Cancer Center and development and clinical validation studies that will be carried out by Diagnostic Oncology CRO, LLC.